Predicting neurodegeneration from sleep related biofluid changes

Yue Yang; Woojin Scott Kim; Johannes C Michaelian; Simon J G Lewis; Craig L Phillips; Angela L D'Rozario; Pratishtha Chatterjee; Ralph N Martins; Ron Grunstein; Glenda M Halliday; Sharon L Naismith

doi:10.1016/j.nbd.2023.106369

Predicting neurodegeneration from sleep related biofluid changes

Neurobiol Dis. 2024 Jan:190:106369. doi: 10.1016/j.nbd.2023.106369. Epub 2023 Dec 3.

Authors

Affiliations

¹ Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia. Electronic address: yue.yang@sydney.du.au.
² Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: woojin.kim@sydney.edu.au.
³ Healthy Brain Ageing Program, School of Psychology, Brain and Mind Centre & The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2050, Australia. Electronic address: johannes.michaelian@sydney.edu.au.
⁴ Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia; Parkinson's Disease Research Clinic, Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia. Electronic address: simon.lewis@sydney.edu.au.
⁵ CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University, Sydney, NSW 2109, Australia; Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia. Electronic address: c.phillips@mq.edu.au.
⁶ Healthy Brain Ageing Program, School of Psychology, Brain and Mind Centre & The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2050, Australia; CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University, Sydney, NSW 2109, Australia. Electronic address: angela.drozario@sydney.edu.au.
⁷ Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia. Electronic address: pratishtha.chatterjee@mq.edu.au.
⁸ Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, NSW 2109, Australia; School of Medical and Health Sciences, Edith Cowan University, Perth, WA 6027, Australia; School of Psychiatry and Clinical Neurosciences, University of Western Australia, Perth, WA 6009, Australia. Electronic address: ralph.martins@mq.edu.au.
⁹ CIRUS, Centre for Sleep and Chronobiology, Woolcock Institute of Medical Research, Macquarie University, Sydney, NSW 2109, Australia; Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2006, Australia. Electronic address: ron.grunstein@sydney.edu.au.
¹⁰ Brain and Mind Centre, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW 2050, Australia; School of Medical Sciences, University of New South Wales, Sydney, NSW 2052, Australia. Electronic address: glenda.halliday@sydney.edu.au.
¹¹ Healthy Brain Ageing Program, School of Psychology, Brain and Mind Centre & The Charles Perkins Centre, The University of Sydney, Sydney, NSW 2050, Australia. Electronic address: sharon.naismith@sydney.edu.au.

PMID: 38049012
DOI: 10.1016/j.nbd.2023.106369

Abstract

Sleep-wake disturbances are common in neurodegenerative diseases and may occur years before the clinical diagnosis, potentially either representing an early stage of the disease itself or acting as a pathophysiological driver. Therefore, discovering biomarkers that identify individuals with sleep-wake disturbances who are at risk of developing neurodegenerative diseases will allow early diagnosis and intervention. Given the association between sleep and neurodegeneration, the most frequently analyzed fluid biomarkers in people with sleep-wake disturbances to date include those directly associated with neurodegeneration itself, such as neurofilament light chain, phosphorylated tau, amyloid-beta and alpha-synuclein. Abnormalities in these biomarkers in patients with sleep-wake disturbances are considered as evidence of an underlying neurodegenerative process. Levels of hormonal sleep-related biomarkers such as melatonin, cortisol and orexin are often abnormal in patients with clinical neurodegenerative diseases, but their relationships with the more standard neurodegenerative biomarkers remain unclear. Similarly, it is unclear whether other chronobiological/circadian biomarkers, such as disrupted clock gene expression, are causal factors or a consequence of neurodegeneration. Current data would suggest that a combination of fluid biomarkers may identify sleep-wake disturbances that are most predictive for the risk of developing neurodegenerative disease with more optimal sensitivity and specificity.

Keywords: Biomarkers; Dementia; Neurodegenerative diseases; Sleep-wake disturbances.

Publication types

Review

MeSH terms

Amyloid beta-Peptides / metabolism
Biomarkers
Humans
Neurodegenerative Diseases*
Sleep / physiology
Sleep Wake Disorders* / diagnosis
Sleep Wake Disorders* / etiology
Sleep Wake Disorders* / metabolism

Substances

Amyloid beta-Peptides
Biomarkers